These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
380 related articles for article (PubMed ID: 27572401)
1. Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing. Castillo-Mancilla J; Seifert S; Campbell K; Coleman S; McAllister K; Zheng JH; Gardner EM; Liu A; Glidden DV; Grant R; Hosek S; Wilson CM; Bushman LR; MaWhinney S; Anderson PL Antimicrob Agents Chemother; 2016 Nov; 60(11):6692-6697. PubMed ID: 27572401 [TBL] [Abstract][Full Text] [Related]
2. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy. Anderson PL; Liu AY; Castillo-Mancilla JR; Gardner EM; Seifert SM; McHugh C; Wagner T; Campbell K; Morrow M; Ibrahim M; Buchbinder S; Bushman LR; Kiser JJ; MaWhinney S Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038282 [TBL] [Abstract][Full Text] [Related]
3. Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates. Chen X; Seifert SM; Castillo-Mancilla JR; Bushman LR; Zheng JH; Kiser JJ; MaWhinney S; Anderson PL PLoS One; 2016; 11(11):e0165505. PubMed ID: 27832147 [TBL] [Abstract][Full Text] [Related]
4. Determination of intracellular tenofovir-diphosphate and emtricitabine-triphosphate concentrations in dried blood spots for pre-exposure prophylaxis adherence. Tsuchiya K; Hayashi Y; Ryu S; Tran HT; Takano M; Tanaka K; Mizushima D; Oka S; Gatanaga H; Hamada A J Infect Chemother; 2024 Sep; 30(9):876-880. PubMed ID: 38431219 [TBL] [Abstract][Full Text] [Related]
5. Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). Hendrix CW; Andrade A; Bumpus NN; Kashuba AD; Marzinke MA; Moore A; Anderson PL; Bushman LR; Fuchs EJ; Wiggins I; Radebaugh C; Prince HA; Bakshi RP; Wang R; Richardson P; Shieh E; McKinstry L; Li X; Donnell D; Elharrar V; Mayer KH; Patterson KB AIDS Res Hum Retroviruses; 2016 Jan; 32(1):32-43. PubMed ID: 26414912 [TBL] [Abstract][Full Text] [Related]
6. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study. Yager J; Castillo-Mancilla J; Ibrahim ME; Brooks KM; McHugh C; Morrow M; McCallister S; Bushman LR; MaWhinney S; Kiser JJ; Anderson PL J Acquir Immune Defic Syndr; 2020 Jul; 84(3):323-330. PubMed ID: 32539288 [TBL] [Abstract][Full Text] [Related]
7. Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing. Spinelli MA; Glidden DV; Anderson PL; Gandhi M; Cohen S; Vittinghoff E; Coleman ME; Scott H; Bacon O; Elion R; Kolber MA; Buchbinder SP; Liu AY J Acquir Immune Defic Syndr; 2019 Jun; 81(2):158-162. PubMed ID: 31095005 [TBL] [Abstract][Full Text] [Related]
8. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. Castillo-Mancilla JR; Zheng JH; Rower JE; Meditz A; Gardner EM; Predhomme J; Fernandez C; Langness J; Kiser JJ; Bushman LR; Anderson PL AIDS Res Hum Retroviruses; 2013 Feb; 29(2):384-90. PubMed ID: 22935078 [TBL] [Abstract][Full Text] [Related]
9. Emtricitabine triphosphate in dried blood spots is a predictor of viral suppression in HIV infection and reflects short-term adherence to antiretroviral therapy. Frasca K; Morrow M; Coyle RP; Coleman SS; Ellison L; Bushman LR; Kiser JJ; Zheng JH; Mawhinney S; Anderson PL; Castillo-Mancilla J J Antimicrob Chemother; 2019 May; 74(5):1395-1401. PubMed ID: 30668713 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of Emtricitabine/Tenofovir Disoproxil Fumarate Among Transgender Adolescents and Young Adults Without HIV Receiving Gender Affirming Hormones. Yager J; Brooks KM; Brothers J; Mulligan K; Landovitz R; Reirden D; Glenny C; Malhotra M; Anderson PL; Hosek S AIDS Res Hum Retroviruses; 2022 Nov; 38(11):840-846. PubMed ID: 35943868 [TBL] [Abstract][Full Text] [Related]
11. Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. Dickinson L; Yapa HM; Jackson A; Moyle G; Else L; Amara A; Khoo S; Back D; Karolia Z; Higgs C; Boffito M Antimicrob Agents Chemother; 2015 Oct; 59(10):6080-6. PubMed ID: 26195515 [TBL] [Abstract][Full Text] [Related]
12. Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men. Shieh E; Marzinke MA; Fuchs EJ; Hamlin A; Bakshi R; Aung W; Breakey J; Poteat T; Brown T; Bumpus NN; Hendrix CW J Int AIDS Soc; 2019 Nov; 22(11):e25405. PubMed ID: 31692269 [TBL] [Abstract][Full Text] [Related]
13. Emtricitabine triphosphate in dried blood spots predicts future viremia in persons with HIV and identifies mismatch with self-reported adherence. Morrow M; MaWhinney S; Coyle RP; Coleman SS; Zheng JH; Ellison L; Bushman LR; Kiser JJ; Anderson PL; Castillo-Mancilla JR AIDS; 2021 Oct; 35(12):1949-1956. PubMed ID: 34127580 [TBL] [Abstract][Full Text] [Related]
14. Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence? Adams JL; Sykes C; Menezes P; Prince HM; Patterson KB; Fransen K; Crucitti T; De Baetselier I; Van Damme L; Kashuba AD J Acquir Immune Defic Syndr; 2013 Mar; 62(3):260-6. PubMed ID: 23111578 [TBL] [Abstract][Full Text] [Related]
15. Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring. Gandhi M; Glidden DV; Liu A; Anderson PL; Horng H; Defechereux P; Guanira JV; Grinsztejn B; Chariyalertsak S; Bekker LG; Grant RM; J Infect Dis; 2015 Nov; 212(9):1402-6. PubMed ID: 25895984 [TBL] [Abstract][Full Text] [Related]
16. Short Communication: Cascade of Antiretroviral Therapy Adherence in Virologically Suppressed Persons Living with HIV. Castillo-Mancilla JR; Coyle RP; Coleman SS; Morrow M; Gardner EM; Zheng JH; Ellison L; Bushman LR; Kiser JJ; MaWhinney S; Anderson PL AIDS Res Hum Retroviruses; 2020 Mar; 36(3):173-175. PubMed ID: 31204866 [TBL] [Abstract][Full Text] [Related]
17. Adherence and HIV Protection Thresholds for Emtricitabine and Tenofovir Disoproxil Fumarate Preexposure Prophylaxis among Cisgender Women: A Systematic Review. Wu L; Niu X; Brunelli MK; Mugwanya KK Curr HIV/AIDS Rep; 2024 Oct; 21(5):264-281. PubMed ID: 39120667 [TBL] [Abstract][Full Text] [Related]
18. A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study. Cressey TR; Siriprakaisil O; Klinbuayaem V; Quame-Amaglo J; Kubiak RW; Sukrakanchana PO; Than-In-At K; Baeten J; Sirirungsi W; Cressey R; Drain PK BMC Infect Dis; 2017 Jul; 17(1):496. PubMed ID: 28705153 [TBL] [Abstract][Full Text] [Related]
19. Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State. Seifert SM; Chen X; Meditz AL; Castillo-Mancilla JR; Gardner EM; Predhomme JA; Clayton C; Austin G; Palmer BE; Zheng JH; Klein B; Kerr BJ; Guida LA; Rower C; Rower JE; Kiser JJ; Bushman LR; MaWhinney S; Anderson PL AIDS Res Hum Retroviruses; 2016; 32(10-11):981-991. PubMed ID: 27526873 [TBL] [Abstract][Full Text] [Related]
20. Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons With HIV Receiving Tenofovir Alafenamide and Emtricitabine-Based Antiretroviral Therapy (QUANTI-TAF). Coyle RP; Morrow M; Mann SC; Mainella V; Ellis SL; Schwab S; Coppinger C; Barker N; Ellison L; Zheng JH; Al Zuabi S; Alpert PE; Carnes TC; Buffkin DE; Chai PR; Bushman LR; Kiser JJ; MaWhinney S; Brooks KM; Anderson PL; Castillo-Mancilla JR Clin Infect Dis; 2024 Nov; 79(5):1233-1241. PubMed ID: 38636950 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]